Thoracic manifestations of collagen vascular diseases

Radiographics

Volumn 32, Issue 1, 2012, Pages 33-50

  Capobianco, Julia ^a   Grimberg, Alexandre ^a   Thompson, Bruna M ^a   Antunes, Viviane B ^a   Jasinowodolinski, Dany ^a   Meirelles, Gustavo S P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLLAGEN DISEASE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METHODOLOGY; RADIOGRAPHY; THORAX DISEASE; THORAX RADIOGRAPHY; VASCULAR DISEASE;

COLLAGEN DISEASES; HUMANS; RADIOGRAPHY, THORACIC; THORACIC DISEASES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 84855752781     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.321105058     Document Type: Article

References (75)

1. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connective tissue diseases. Clin Chest Med 2008;29(1):149-164.
2. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009;103(8): 1152-1158.
3. Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. RadioGraphics 2009;29(1):73-87.
4. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15(2):373-381.
5. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165(2):277-304. [Published correction appears in Am J Respir Crit Care Med 2002;166(3):426.]
6. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. RadioGraphics 2002;22(spec issue):S151-S165.
7. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44(6): 585-596.
8. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008;177(12):1338-1347.
9. Silva CI, Müller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008;246(1):288-297.
10. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009;50(4):538-545.
11. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162(6):2213-2217.
12. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164 (7):1182-1185.
13. Papiris SA, Vlachoyiannopoulos PG, Maniati MA, Karakostas KX, Constantopoulos SH, Moutsopoulos HH. Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses. Respiration 1997;64 (1):81-85.
14. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149(6): 1583-1590.
15. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009;33(1):68-76.
16. Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009;30(4):369-375.
17. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002;19(3):571-576.
18. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21(5):467-474.
19. Hinderliter AL, Willis PW 4th, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Am J Cardiol 1999;84(4):481-484, A10.
20. Pamboucas C, Nihoyannopoulos P. Cardiovascular magnetic resonance: its role in the diagnosis and evaluation of pulmonary arterial hypertension [in Spanish]. Rev Esp Cardiol 2006;59(8):755-760.
21. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006; 12(5):346-353.
22. Franquet T. High-resolution CT of lung disease related to collagen vascular disease. Radiol Clin North Am 2001;39(6):1171-1187.
23. Lieberman-Maran L, Orzano IM, Passero MA, Lally EV. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature-implications for management with biologic response modifiers. Semin Arthritis Rheum 2006;35(6): 379-387.
24. Brazeau-Lamontagne L, Charlin B, Levesque RY, Lussier A. Cricoarytenoiditis: CT assessment in rheumatoid arthritis. Radiology 1986;158(2): 463-466.
25. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127(6): 2019-2027.
26. Hakala M, Pääkkö P, Sutinen S, Huhti E, Koivisto O, Tarkka M. Association of bronchiolitis with connective tissue disorders. Ann Rheum Dis 1986;45 (8):656-662.
27. Aquino SL, Webb WR, Golden J. Bronchiolitis obliterans associated with rheumatoid arthritis: findings on HRCT and dynamic expiratory CT. J Comput Assist Tomogr 1994;18(4):555-558.
28. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979;119(3):471-503.
29. Srinivas S, Dhelaria R, Pai D, Black F, Cooper R. Multiple calcified pulmonary nodules: an unusual presentation of rheumatoid lung. Clin Radiol 2007; 62(3):274-276.
30. Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 1953;8(1):29-37.
31. Lindars DC, Davies D. Rheumatoid pneumoconiosis: a study in colliery populations in the East Midlands coalfield. Thorax 1967;22(6):525-532.
32. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43(2):143-147.
33. Coral-Alvarado P, Pardo AL, Castaño-Rodriguez N, Rojas-Villarraga A, Anaya JM. Systemic sclerosis: a world wide global analysis. Clin Rheumatol 2009;28(7):757-765.
34. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48(suppl 3):iii40-iii44.
35. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001;60(3): 281-283.
36. Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007;22(2):120-124.
37. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124(5):477-484.
38. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3): iii25-iii31.
39. Mayberry JP, Primack SL, Müller NL. Thoracic manifestations of systemic autoimmune diseases: radiographic and high-resolution CT findings. RadioGraphics 2000;20(6):1623-1635.
40. Marasini B, Conciato L, Belloli L, Massarotti M. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009;22(3):573-578.
41. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39(4):257-268.
42. Good JT Jr, King TE, Antony VB, Sahn SA. Lupus pleuritis: clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest 1983;84(6):714-718.
43. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54(8):2550-2557.
44. Kinder BW, Freemer MM, King TE Jr, et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum 2007; 56(8):2679-2686.
45. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006;15(11):778-783.
46. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 2009;23(4):469-480.
47. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000;6(5):424-429.
48. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975;54(5):397-409.
49. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990;20 (1):48-56.
50. Gladman DD, Urowitz MB. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis 1980;39(4):340-343.
51. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112(9):682-698.
52. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997;76(3): 192-202.
53. Hoffbrand BI, Beck ER. "Unexplained" dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ 1965;1(5445):1273-1277.
54. Martens J, Demedts M, Vanmeenen MT, Dequeker J. Respiratory muscle dysfunction in systemic lupus erythematosus. Chest 1983;84(2):170-175.
55. Begum S, Li C, Wedderburn LR, Blackwell V, Isenberg DA. Concurrence of sarcoidosis and systemic lupus erythematosus in three patients. Clin Exp Rheumatol 2002;20(4):549-552.
56. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362(9388):971-982.
57. Schwarz MI. The lung in polymyositis. Clin Chest Med 1998;19(4):701-712.
58. Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984;289 (6438):151-152.
59. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with polymyositis/dermatomyositis. Intern Med 2002;41(12):1135-1141.
60. Polverosi R, Maffesanti M, Dalpiaz G. Organizing pneumonia: typical and atypical HRCT patterns. Radiol Med (Torino) 2006;111(2):202-212.
61. Voloudaki AE, Bouros DE, Froudarakis ME, Datseris GE, Apostolaki EG, Gourtsoyiannis NC. Crescentic and ring-shaped opacities: CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP). Acta Radiol 1996;37(6):889-892.
62. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357(9250):96-100.
63. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52(2):148-159.
64. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42(5): 899-909.
65. Bodolay E, Szekanecz Z, Dévényi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 2005;44(5):656-661.
66. Fagundes MN, Caleiro MT, Navarro-Rodriguez T, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 2009;103(6):854-860.
67. Crestani B. The respiratory system in connective tissue disorders. Allergy 2005;60(6):715-734.
68. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren's syndrome. Clin Chest Med 1998;19(4):687-699.
69. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554-558.
70. Papiris SA, Saetta M, Turato G, et al. CD4-positive T-lymphocytes infiltrate the bronchial mucosa of patients with Sjögren's syndrome. Am J Respir Crit Care Med 1997;156(2 pt 1):637-641.
71. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest 2006;130(5):1489-1495.
72. Lynch DA. Lung disease related to collagen vascular disease. J Thorac Imaging 2009;24(4):299-309.
73. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89(6):888-892.
74. Honda O, Johkoh T, Ichikado K, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol 1999;173(1):71-74.
75. Rosenow E, Strimlan CV, Muhm JR, Ferguson RH. Pleuropulmonary manifestations of ankylosing spondylitis. Mayo Clin Proc 1977;52(10):641-649.